CereGate closes over-subscribed Series C financing round
Round led by a global US-based medtech company, with Impact Ventures joining as a new investor
MUNICH, [14/10/2026] — CereGate GmbH, a clinical-stage neurotechnology company developing brain-computer interface (BCI) technology for the treatment of neurological disorders, today announced the closing of an over-subscribed Series C financing round. The round is led by a global US-based medtech company, with strong support from existing investors as well as Impact Ventures, based in Budapest. The company's current focus is on clinical development.
CereGate software runs on Boston Scientific deep brain stimulation systems and is currently in clinical investigation. Its first clinical indication is freezing of gait (FoG), a sudden interruption of walking that persists in a proportion of Parkinson's patients despite optimized medication and responds poorly to established forms of deep brain stimulation. Separately, the company conducts research in spinal cord stimulation.
"We are proud to have won a strategic investor of this calibre for this round, and we are equally glad to have Impact Ventures on board, who understood the clinical opportunity early. The round allows us to take our therapy through the clinical work that matters most, in an indication where few options remain once medication and standard stimulation stop working," said Matthias Puls, chief executive officer, CereGate GmbH.
Partners
Truventuro
TruVenturo is one of the leading company builders in Europe, investing at the forefront of digitalization and life sciences. TruVenturo’s current portfolio includes over 20 companies, among them several industry leaders and hidden champions.
468
468 Capital is a venture capital investor focusing on European tech companies. Founded in 2020 by Alexander Kudlich, Florian Leibert and Ludwig Ensthaler, 468 Capital invests in pre-seed and early growth phases of a company. 468 Capital offers portfolio companies not only financial resources, but also strategic support as well as access to US growth funds.
Re.Mind
re.Mind Capital is a mental & neurological health venture fund, founded by Christian Angermayer, Max de Vere and Jan Hardorp. Angermayer is best-known for his pioneering investments into psychedelics-based treatments for mental health, and is a co-founder of atai Life Sciences. re.Mind’s first fund manages USD 150m, making it the largest early-stage fund dedicated to the brain. With around 20 portfolio companies to date, they invest into companies in neurotech/BCI, biotech, digital tools, and new treatment modalities.
High-Tech Gründerfonds
HTGF is a venture capital investor for innovative technologies and business models.
Healcapital
Heal Capital is a European venture capital fund backing mission-driven founders with capital and HealthTech-specific expertise, accelerating market access.
CARMA FUND
CARMA FUND I is an early-stage investment fund for advancing the translation of Life Science and Healthcare assets.
Impact Ventures
Impact Ventures is a European impact investment fund supporting innovative companies that generate measurable positive social and environmental impact alongside financial returns.
